TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 90 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q1 2017. The put-call ratio across all filers is 0.18 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $250,000 | -66.7% | 519,909 | -7.2% | 0.00% | -66.7% |
| Q1 2019 | $750,000 | +72.0% | 560,225 | +45.4% | 0.00% | +50.0% |
| Q4 2018 | $436,000 | -63.5% | 385,286 | -11.1% | 0.00% | -60.0% |
| Q3 2018 | $1,196,000 | +702.7% | 433,478 | +937.7% | 0.01% | +400.0% |
| Q2 2018 | $149,000 | -70.4% | 41,774 | -74.5% | 0.00% | -50.0% |
| Q1 2018 | $503,000 | -44.5% | 163,898 | +28.9% | 0.00% | -50.0% |
| Q2 2017 | $907,000 | -74.0% | 127,171 | -66.4% | 0.00% | -75.0% |
| Q1 2017 | $3,482,000 | +374.4% | 379,049 | +108.2% | 0.02% | +300.0% |
| Q4 2016 | $734,000 | +367.5% | 182,027 | +345.7% | 0.00% | +300.0% |
| Q3 2016 | $157,000 | -38.9% | 40,845 | -31.9% | 0.00% | 0.0% |
| Q2 2016 | $257,000 | – | 59,986 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 1,048,642 | $3,219,000 | 0.50% |
| Virtus ETF Advisers LLC | 130,920 | $402,000 | 0.35% |
| 683 Capital Management, LLC | 600,000 | $1,842,000 | 0.16% |
| Tekla Capital Management LLC | 859,322 | $2,638,000 | 0.10% |
| DOW CHEMICAL CO /DE/ | 65,000 | $200,000 | 0.07% |
| Alambic Investment Management, L.P. | 115,834 | $356,000 | 0.05% |
| A.R.T. Advisors, LLC | 262,896 | $807,000 | 0.03% |
| Candriam S.C.A. | 520,613 | $1,598,000 | 0.03% |
| Man Group plc | 1,674,341 | $5,140,000 | 0.02% |
| Baker Brothers Advisors | 935,000 | $2,870,000 | 0.02% |